Managing the Morbidity Associated with Respiratory Viral Infections in Children with Congenital Heart Disease
Open Access
- 29 February 2012
- journal article
- review article
- Published by Hindawi Limited in International Journal of Pediatrics
- Vol. 2012, 1-8
Abstract
Children with congenital heart disease (CHD) are at risk for increased morbidity from viral lower respiratory tract infections because of anatomical cardiac lesions than can worsen an already compromised respiratory status. Respiratory syncytial virus (RSV) remains an important pathogen in contributing toward the morbidity in this population. Although the acute treatment of RSV largely remains supportive, the development of monoclonal antibodies, such as palivuzumab, has reduced the RSV-related hospitalization rate in children with CHD. This review highlights the specific cardiac complications of RSV infection, the acute treatment of bronchiolitis in patients with CHD, and the search for new therapies against RSV, including an effective vaccine, because of the high cost associated with immunoprophylaxis and its lack of reducing RSV-related mortality.Keywords
This publication has 64 references indexed in Scilit:
- Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or MotavizumabThe Journal of Infectious Diseases, 2011
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentImmunological Reviews, 2010
- Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infectionBMC Infectious Diseases, 2010
- The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic childrenJournal of Allergy and Clinical Immunology, 2010
- Viral respiratory tract infections and asthma: The course aheadJournal of Allergy and Clinical Immunology, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusProceedings of the National Academy of Sciences of the United States of America, 2010
- Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart DiseasePediatric Cardiology, 2009
- Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infantsArchives of Disease in Childhood, 2009
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009